We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alpha-1-Antitrypsin Gene Replacement Therapy Cures Emphysema in Mouse Model

By LabMedica International staff writers
Posted on 19 Jul 2016
Print article
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
Image: A crystal structure model of the surface of the AAV-2 serotype of adeno-associated virus (Photo courtesy of Wikimedia Commons).
A virus-like vector loaded with the gene for production of the enzyme alpha-1-antitrypsin (AAT) successfully established production of the protein in the lungs of mice serving as a model for human emphysema.

Alpha-1-antitrypsin protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. In its absence (such as in alpha 1-antitrypsin deficiency or AATD), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs, resulting in respiratory complications such as emphysema, or COPD (chronic obstructive pulmonary disease) in adults and cirrhosis in adults or children.

Gene therapy to reinstate AAT production in emphysema patients has been considered as an attractive alternative to the current therapy regime of weekly intravenous infusion of the normal AAT protein.

In one approach to developing gene therapy for treatment of emphysema, investigators at Boston Medical College (MA, USA) used a lung-targeted adeno-associated virus (AAV) vector to transport the AAT gene (SERPINA1) to the lungs of mice serving as a model for the human disease.

The investigators reported in the June 29, 2016, online edition of the journal Molecular Therapy - Methods & Clinical Development that the genes delivered in a single injection of lung-directed AAV2/8 were able to achieve therapeutic AAT protein levels within the lung epithelial lining fluid, and that gene expression persisted for at least 52 weeks. Enzyme levels reached after AAT gene delivery were sufficient to relieve the severity of experimental emphysema in the mice. They also found that the same injection of AAV2/8 efficiently transduced liver cells, a finding that may have significance for AAV-based human gene therapy studies.

"These results support direct transgene delivery to the lung as a potential alternative approach to achieve the goal of developing a gene therapy for AATD," said senior author Dr. Andrew Wilson, assistant professor of medicine at Boston Medical College.

Related Links:
Boston Medical College


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more